Previous 10 | Next 10 |
NovoCure (NVCR) sees Q4 revenue of $144.0 (+45% Y/Y) vs. a consensus $133.62M.Full year 2020 net revenues of $494.4M (+41% Y/Y).Asaf Danziger, Novocure’s CEO. “Through our clinical and product development efforts, we believe we are just beginning to unlock the potential of ...
Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019 Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 Fourth quarter and full...
Novocure (NASDAQ: NVCR) will participate virtually in the 39 th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. ...
The Swiss Federal Office of Public Health ((BAG)) has added Novocure's (NVCR) Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma ((GBM)), effective April 1, 2021.The List of Remedies and Eq...
Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The...
Novocure ([[NVCR]] +5.0%) has enrolled the first patient in its Phase 3 TRIDENT trial, in newly diagnosed glioblastoma testing the potential survival benefit of initiating Optune concurrent with radiation therapy. Optune is a noninvasive, antimitotic cancer treatment that delivers Tumor ...
TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage rep...
The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...
Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3 rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle and Dr. We...
Shares of Novocure (NASDAQ: NVCR) were sinking 9.2% as of 3:30 p.m. on Tuesday. The oncology therapy company didn't announce any news, so why did the stock fall on a day when the overall market soared? The most likely reason is that some investors decided to lock in profits after No...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...